Urovant Sciences Ltd (NASDAQ:UROV) Q1 2019 Earnings Conference Call - Final Transcript
Aug 13, 2019 • 04:30 pm ET
Keith A. Katkin
what the data looked like. So we obviously view this is a very significant opportunity as we get closer and closer to launch to appropriately educate the doctors on this risk and also to appropriately educate patients on this risk. But to doctors and patients that we have exposed to the information, and the patients, almost all of them want to switch off of an anticholinergics therapy immediately upon learning this information. And then for clinicians, they may want more information, they really want to understand the risks so they can make the appropriate tradeoffs with their patients.
Great. Thanks for taking the questions.
Keith A. Katkin
Thank you. Our next question comes from Joon Lee of SunTrust Robinson. Your line is open.
Hi. Thanks for the question and congrats on all your progress. One of the things I was surprised to learn is that, in your presentation you mention about 2.4 million patients or about 70% of patients on drug discontinued. Can you discuss some of the main reasons for discontinuation and whether the efficacy demonstrated by your -- by vibegron in Phase 3 EMPOWUR study is adequate to address those deficiencies in order to be commercially successful? And I have a follow-up. Thank you.
Keith A. Katkin
Great. Thanks, Joon. So the -- I think what you're referring to is we believe that about 3.3 million patients start oral therapy every year. Over 70% of them discontinued within that first year or so, there's about 2.4 million patients that are back in the pool looking for a new treatment option every year which is likely why most all products that have been launched for OAB have been quite successful with most of them achieving blockbuster status. We think that the reason for the high drop out rate is really two-fold. If you're talking about the anticholinergics, which is a majority of the prescriptions. Anticholinergics, if you look at the package inserts, you can see that many of them are associated with very high rates of constipation, very high rates of dry mouth and some have even had a new label update, talking about cognitive concern and ability to cause agitation.
So what we believe is that as the patients are dealing with all of those side effects, they're looking at that relative to the relief that they're getting after their OAB and they just are coming to the conclusion that it's not worth it. And then therefore, go back into the treatment pool, which is why we believe Myrbetriq has been so successful since being launched in 2012.
Changing gears to Myrbetriq though, and looking at that information. We believe that a high percentage of patients using Myrbetriq early in the product -- early with the products use, because many patients, our data shows about 50% of patients are on the 25 milligram dose, and due to that starting dose, patients aren't getting the full adequate relief that they could get if they dose titrated, but these patients, well, it's got a